<DOC>
	<DOCNO>NCT02486718</DOCNO>
	<brief_summary>This Phase III , global , multicenter , open-label , randomize study compare efficacy safety 16 cycle ( 1 cycle duration=21 day ) atezolizumab ( MPDL3280A ) treatment compare best supportive care ( BSC ) participant Stage IB-Stage IIIA non-small cell lung cancer ( NSCLC ) follow resection adjuvant chemotherapy , measure disease-free survival ( DFS ) assess investigator overall survival ( OS ) . Participants , complete 4 cycle adjuvant cisplatin-based chemotherapy , randomize 1:1 ratio receive atezolizumab 16 cycle BSC .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Atezolizumab ( MPDL3280A ) Compared Best Supportive Care Following Chemotherapy Patients With Lung Cancer IMpower010</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Enrollment Phase Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histological cytological diagnosis Stage IB ( tumor great equal [ &gt; /= ] 4 centimeter [ cm ] ) IIIA ( T23 N0 , T13 N1 , T13 N2 , T4 N01 ) NSCLC ( per Union Internationale Contre le Cancer staging system ( UICC ) /American Joint Committee Cancer stag system ( AJCC ) stag system , 7th edition ; Detterbeck et al . 2009 ) Participants must complete resection NSCLC 412 week ( &gt; /=28 day less equal [ &lt; /= ] 84 day ) prior enrollment must adequately recover surgery If mediastinoscopy perform preoperatively , require , minimum , mediastinal lymph node systematic sampling occur . Systematic sampling define removal least one representative lymph node specify level . MLND entail resection lymph node level . For right thoracotomy , sample MLND require level 4 7 leave thoracotomy , level 5 and/or 6 7 . Exceptions grant clear documentation operative report separately submit addendum surgeon exploration require lymph node area , participant consider eligible lymph node find area ; participant document N2 disease one level ( per UICC/AJCC stag system , 7th edition ; Detterbeck et al . 2009 ) , level need sample ; preoperative stag image result ( contrast compute tomography [ CT ] positron emission tomography [ PET ] scan ) suggest evidence disease mediastinum , participant consider eligible N2 nodal sample perform per surgeon 's decision Eligible receive cisplatinbased chemotherapy regimen Adequate hematologic endorgan function Women postmenopausal ( &gt; /=12 month nontherapyinduced amenorrhea ) surgically sterile must negative serum pregnancy test result within 14 day prior initiation cisplatinbased chemotherapy Inclusion Criteria Randomized Phase Women postmenopausal ( &gt; /=12 month nontherapyinduced amenorrhea ) surgically sterile must negative serum pregnancy test result within 14 day prior initiation atezolizumab BSC Exclusion Criteria Enrollment Phase Illness condition may interfere participant 's capacity understand , follow , and/or comply study procedure Pregnant lactate woman Treatment prior systemic chemotherapy : Chemotherapy early stage malignancy curative intent , provide last dose receive 5 year prior enrollment lowdose chemotherapy nonmalignant condition may allow upon approval Medical Monitor Hormonal cancer therapy radiation therapy prior cancer treatment within 5 year enrollment Treatment investigational agent therapeutic intent within 28 day prior enrollment Participants hear impairment Known sensitivity component chemotherapy regimen participant assign , mannitol Prior treatment cluster differentiation ( CD ) 137 ( CD137 ) agonists immune checkpoint blockade therapy , antiprogrammed death1 ( PD1 ) , anti program death ligand 1 ( PDL1 ) therapeutic antibody Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death ( e.g. , expect 5year OS great [ &gt; ] 90 percent [ % ] ) treat expected curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation History autoimmune disease , include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis Positive test human immunodeficiency virus ( HIV ) Participants active hepatitis B ( chronic acute ; define positive hepatitis B surface antigen [ HBsAg ] test screening ) hepatitis C Active tuberculosis Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction , cerebrovascular accident within previous 3 month , unstable arrhythmia , unstable angina History idiopathic pulmonary fibrosis , organize pneumonia ( e.g. , bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan Prior allogeneic bone marrow transplantation solid organ transplant Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication Known tumor PDL1 expression status determine immunohistochemistry ( IHC ) assay clinical study ( e.g. , participant whose PDL1 expression status determine screen entry study antiPD1 antiPDL1 antibody eligible exclude ) Specific Exclusions Pemetrexed Treatment Participants squamous cell histology Exclusion Criteria Randomized Phase Signs symptom infection within 14 day prior randomization ( severe infection within 28 day prior randomization ) , include limited hospitalization complication infection , bacteremia , severe pneumonia Received therapeutic oral intravenous ( IV ) antibiotic within 14 day prior randomization Major surgical procedure within 28 day prior randomization anticipation need major surgical procedure course study Administration live , attenuated vaccine within 28 day prior randomization anticipation live attenuate vaccine require study Treatment systemic immunostimulatory agent ( include limit interferon interleukin2 ) within 4 week 5 halflives drug , whichever longer , prior randomization : Prior treatment cancer vaccine allow Treatment systemic corticosteroid immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 14 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>